Also known as alpha-Klotho · Klotho · soluble Klotho · sKlotho · KL
The aging-associated protein whose circulating ectodomain is the FGF23 co-receptor — a recombinant glycoprotein, studied in phosphate balance and kidney disease.
Research refreshed
α-Klotho (gene KL) is a type I transmembrane protein. The full chain is 1,012 residues (UniProt Q9UEF7): a short signal, a large extracellular region of two glycosidase-like domains (KL1 and KL2), a single transmembrane span, and a short cytoplasmic tail. Proteases shed the extracellular piece into blood and cerebrospinal fluid; that soluble ectodomain, roughly Glu34–Ser981, is the form supplied as recombinant “soluble klotho.” It is not an approved medicine. It is also not β-klotho, the separate gene (KLB) that pairs with FGF21.
Kuro-o and colleagues (Nature, 1997) found klotho by accident: mice with a disrupted promoter aged fast — shortened lifespan, arterial calcification, skin atrophy, and osteoporosis — and restoring the gene prevented that picture. The protein those mice lacked is a membrane glycoprotein expressed mainly in the kidney distal tubule and the choroid plexus. The circulating activity is the ectodomain, cut loose by ADAM proteases and related sheddases. A separately spliced isoform contains only KL1 and is a minor species next to the shed two-domain form.
The function that made the protein tractable is phosphate, not a generic “anti-aging” activity. Membrane and soluble α-klotho both assemble with FGF receptors so that FGF23 can signal (Kurosu et al., and Urakawa et al., Journal of Biological Chemistry 2006). FGF23 then lowers renal phosphate reabsorption. Klotho-deficient and FGF23-deficient mice look alike, which is why the two are read as one axis. In chronic kidney disease that axis is disordered, and recombinant soluble klotho is studied as a way to put the co-receptor back — still investigational.
The research material is a glycoprotein, not a synthetic peptide. The naked ectodomain polypeptide is about 110 kDa; N-glycosylation pushes the circulating and recombinant protein to about 120–130 kDa on SDS-PAGE, and the mass and charge depend on the cell line that made it (CHO versus HEK). A product labeled only “klotho” can be the full ectodomain or the shorter KL1-only splice form (~65–70 kDa). β-Klotho is a different protein and the co-receptor for FGF21, so an identity test has to say which gene was expressed.
Obligate co-receptor with FGF receptors for fibroblast growth factor 23. The Klotho–FGFR complex lets FGF23 lower phosphate reabsorption in the kidney and suppress vitamin D activation. The shed ectodomain retains co-receptor activity. A weaker, FGF23-independent glycosidase-like activity toward ion-channel and transporter glycans is also reported; the catalytic glutamates of a true family-1 glycosidase are not both present.
Behind every vial of α-Klotho is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how α-Klotho, specifically, is brought into being.
On paper, α-Klotho weighs in at roughly 130,000 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
α-Klotho is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — α-Klotho plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of α-Klotho proves itself: identity confirmed by mass spectrometry against its ~130,000 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of α-Klotho — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
α-Klotho is not a solid-phase peptide. The soluble research material is the extracellular region (UniProt Q9UEF7, approximately residues 34–981) expressed in mammalian cells so it is N-glycosylated. The polypeptide mass is about 110 kDa; the glycosylated protein migrates at about 120–130 kDa, and sialylation — and therefore charge — differs between CHO and HEK production. The KL1-only splice is a different, smaller protein (~65–70 kDa). Identity is the expression construct and the glycan pattern, not a single molecular formula.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning α-Klotho, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
α-Klotho is a kidney- and choroid-plexus-enriched transmembrane protein. Its shed extracellular domain circulates and is the co-receptor that lets FGF23 regulate phosphate. Recombinant soluble klotho is that ectodomain, produced in mammalian cells.
The membrane protein is the full 1,012-residue chain. Soluble klotho is the extracellular piece (about Glu34–Ser981) released by proteases. A minor spliced form contains only the first of the two extracellular domains. Glycosylation puts the two-domain soluble protein near 120–130 kDa.
No. β-Klotho is a separate gene, KLB, and it is the co-receptor for FGF21. α-Klotho pairs with FGF23. A vial marked only “klotho” has not said which one it is.
No — this is a research and educational reference. Soluble klotho is investigational and is not an approved medicine.
The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewRecombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.